MicroRNAs act as post-transcriptional regulators, tuning gene expression without changing DNA sequences. In this work, miR-195-5p is positioned as a key controller of apoptotic signaling, influencing how colorectal cancer cells respond to internal stress and growth cues. Rather than affecting a single target in isolation, the molecule appears to coordinate a broader balance between pro-death and pro-survival factors.

Central to the findings is the XIAP/BCL2/Survivin axis. XIAP (X-linked inhibitor of apoptosis protein) is a well-known brake on caspase activity, helping cells avoid programmed death. BCL2, a mitochondrial guardian of survival, counteracts apoptotic membrane permeabilization. Survivin further complicates the picture by supporting cell division while also contributing to apoptosis resistance.

According to the authors, miR-195-5p suppresses this survival triad, reducing the protective effect each protein provides. By lowering XIAP and BCL2 and diminishing Survivin-mediated persistence, the cancer cells lose multiple layers of defense at once. The resulting shift promotes progression of the apoptotic cascade, increasing the likelihood that stressed tumor cells undergo programmed cell death.

This “network-level” approach is particularly notable in oncology, where single-target strategies often face rapid compensation. The study’s emphasis on coordinated regulation supports the idea that microRNA-based interventions may yield more durable biological effects than perturbing one pathway component alone.

The experimental framework links miR-195-5p expression patterns to functional outcomes in colorectal cancer models, tying molecular changes to measurable apoptosis-related responses. Overall, the data argue that miR-195-5p functions as a tumor-inhibitory regulator capable of disarming the apoptosis resistance machinery.

If these mechanisms translate beyond preclinical contexts, miR-195-5p could represent a candidate for therapeutic development aimed at restoring cell-death competency. More broadly, the work underscores how microRNAs can serve as network governors, integrating signals across apoptosis and survival pathways.

By placing the XIAP/BCL2/Survivin network under miR-195-5p control, the study offers a clear mechanistic story for how apoptosis can be reactivated in colorectal cancer. It also provides a target-rich framework for future work exploring combination strategies that pair miRNA modulation with existing anti-cancer regimens.

Subject of Research: miR-195-5p regulation of apoptosis in colorectal cancer

Article Title: miR-195-5p controls apoptotic cascade by regulating the XIAP/BCL2/Survivin network in colorectal cancer

Article References: Piccinno, E., Scalavino, V., Bianco, G. et al. miR-195-5p controls apoptotic cascade by regulating the XIAP/BCL2/Survivin network in colorectal cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03280-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03280-y

MicroRNAs function as post-transcriptional regulators: they fine-tune which proteins cells produce and, by doing so, help maintain protein homeostasis (proteostasis). Proteostasis supports proper folding, turnover, and balance of the proteome; when it collapses, cells can shift toward dysfunctional survival programs—an enabling step in cancer.

The work centers on the idea that microRNAs act like molecular traffic lights for cell-state decisions. According to the study’s lead investigator, disrupting proteostasis is a key reason many cancer cells become cancerous. By reintroducing microRNA-15a and microRNA-16 into NSCLC cells, the researchers observed a partial re-establishment of normal regulatory constraints that control metabolism and growth.

Mechanistically, the approach targets signaling downstream of gene expression rather than a single oncogenic protein. This matters because cancer frequently reflects network failures: when multiple “brakes” on cell division are removed, cells can enter a self-reinforcing cycle of growth. MicroRNA replacement appears to restore some of these brakes by altering proteostasis-related pathways.

The investigators emphasize translational caution. The results do not claim cure; instead, they propose that microRNA-based therapy might arrest or slow disease enough to create time for combination treatment. In clinical oncology, such time could improve the effectiveness of surgery, radiation, or pharmacologic regimens delivered later.

The microRNAs were not initially discovered in cancer research. Fluckey’s lab began with skeletal muscle biology, where microRNAs help regulate muscle growth, protein turnover, and insulin sensitivity. Building on those observations, the team suspected the same regulatory RNAs might influence tumor behavior.

Future therapy development will likely require delivery systems that preferentially enter cancer cells while limiting exposure to healthy tissue. One envisioned strategy uses engineered viral vectors to deliver therapeutic genetic material carrying the microRNA program.

The study also highlights the value of cross-disciplinary collaboration within Texas A&M, linking investigators with complementary expertise to generate new experimental directions.

Subject of Research: Cells
Article Title: MicroRNA 15a and 16 Regulate Proteostasis in Non-Small Cell Lung Cancer
News Publication Date: 2-May-2026
Web References: https://pubmed.ncbi.nlm.nih.gov/42077822/
References: 10.1096/fba.2026-00075
Image Credits: Texas A&M University

Keywords: microRNA, lung cancer, NSCLC, proteostasis, proteostasis regulation, molecular regulation, RNA therapeutics, cellular growth control, viral delivery

Traditionally, cancer has been viewed primarily through the lens of genomic mutations—faulty DNA instructions that lead to unchecked cellular proliferation. However, mounting evidence suggests that this genomic narrative is incomplete without considering epitranscriptomics—the chemical modification of RNA molecules that regulate gene expression post-transcriptionally. RNA modifications, especially methylation on tRNAs and ribosomal RNAs, play a pivotal role in fine-tuning protein synthesis. Disruptions in these modifications may reprogram cancer cells’ protein production machinery, enabling malignancy and therapeutic resistance.

The helm of this pioneering endeavor is Professor James Williamson, the Cecil H. and Ida M. Green Chair of Chemistry at Scripps Research. Collaborating with him are esteemed scientists Gary Siuzdak, also from Scripps, specializing in metabolomics, and Rachel Green, a Bloomberg Distinguished Professor at Johns Hopkins University School of Medicine. Over the course of the next five years, their integrated approach will scrutinize the dynamic landscape of RNA modifications in the context of cancer and nutrient availability, with funding nearing $5 million contingent on ongoing approvals.

Central to their focus is the phenomenon of methylation influenced by methionine, an essential amino acid found abundantly in protein-rich diets. Methionine serves as the primary methyl donor in various cellular processes, including the methylation of RNA molecules. Both ribosomes and transfer RNAs, critical players in protein synthesis, bear numerous methyl groups that shape their function. The availability of methionine thus critically regulates these epitranscriptomic marks, with direct implications for how cancer cells modulate their proteome in response to environmental cues.

Recent studies have underscored the potential of dietary methionine restriction as a strategy to curb cancer growth, yet the molecular underpinnings of this phenomenon remain poorly defined. This research aims to bridge that gap by dissecting how methionine scarcity remodels the chemical landscape of RNA within cancer cells. Using advanced mass spectrometry, Williamson’s laboratory will precisely map alterations in methylation and other modifications on ribosomal RNAs and tRNAs, providing a molecular atlas of response to nutrient stress.

Complementing this, Siuzdak’s metabolomics expertise will illuminate shifts in the intracellular availability of methionine and related metabolites, revealing how fluctuations in nutrient pools interface with epitranscriptomic remodeling. This integrative analysis promises unprecedented insights into the metabolic-epitranscriptomic crosstalk that governs cancer cell survival and proliferation under nutrient-limiting conditions.

To translate these molecular alterations into functional outcomes, Rachel Green’s team will employ ribosome profiling, an innovative method that captures snapshots of active translation across the cancer cell genome. By quantifying which mRNAs are preferentially translated and which are downregulated in response to altered RNA modifications, the researchers can connect molecular changes directly to shifts in protein synthesis—a critical determinant of cancer cell behavior.

Such mechanistic clarity is vital, as it could unveil novel therapeutic targets aimed at disrupting cancer’s adaptive translational program. Understanding how methionine-driven methylation patterns sculpt the proteomic landscape offers a tangible entry point for interventions. It could also rationalize and refine dietary methionine restriction protocols, enhancing their efficacy and applicability across diverse cancer types.

Beyond methylation, this initiative is poised to pioneer a broader exploration of RNA modifications—chemical tags that extend well beyond methyl groups and whose roles in oncogenesis remain largely uncharted. By establishing robust frameworks and methodological paradigms, the project sets a foundation for future studies to chart the complex epitranscriptomic networks in cancer.

The implications of this research extend beyond cancer, as RNA modifications have emerged as fundamental regulators of cellular physiology in health and disease. The ability to dynamically modulate protein synthesis through chemical tags on RNA offers a versatile regulatory layer with far-reaching biological significance.

This pioneering work is a testament to the power of interdisciplinary collaboration, blending chemistry, metabolomics, and molecular biology to tackle the intricate metabolic and molecular labyrinth of cancer. By focusing on the metabolic basis of epitranscriptomic changes, the researchers cast light on the profound ways in which nutrient signals influence cancer progression.

As cancer therapeutics evolve towards precision medicine, understanding the nuanced interplay between metabolism and gene expression at the RNA level will be crucial. This research paves the way for innovative therapeutic strategies that exploit cancer cells’ metabolic vulnerabilities, potentially leading to treatments with higher specificity and fewer side effects.

Funded under award number 1U01CA305256-01, this RNAMoDO program project reflects the cutting edge of cancer research, promising to illuminate the RNA modifications that drive oncogenesis and to open new avenues for intervention.

Through this comprehensive and multifaceted investigation, Scripps Research, alongside Johns Hopkins University, is set to redefine our grasp of cancer biology—shifting from a purely genetic perspective to one that embraces the dynamic and complex chemical alphabet written on RNA.

Subject of Research:
RNA modifications influencing cancer cell growth and methionine-dependent methylation processes

Article Title:
Scripps Research Leads Transformative Study on RNA Modifications and Nutrient-Driven Cancer Growth

News Publication Date:
Information not provided

Web References:
https://www.scripps.edu/faculty/williamson/
https://www.scripps.edu/faculty/siuzdak/
https://reporter.nih.gov/search/7T3nB_MDg0O7_j1rVJ3SXA/project-details/11226464

Image Credits:
Credit: Scripps Research

Keywords:
Cancer, RNA modifications, methylation, methionine restriction, ribosome profiling, metabolomics, translational control, epitranscriptomics, Scripps Research, National Cancer Institute, RNAMoDO program